Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: The unseen impact of the fiscal crisis - The Health Outcomes Patient Environment (HOPE) study

Rheumatology International

Volumn 34, Issue 1, 2014, Pages 25-33

  Souliotis, Kyriakos ^a,b   Papageorgiou, Manto ^b   Politi, Anastasia ^c   Ioakeimidis, Dimitrios ^d   Sidiropoulos, Prodromos ^e  

^a UNIVERSITY OF PELOPONNESE   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Oral Medicine Clinic National Organization for the Provision of Health Services (IKA)   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e UNIVERSITY OF CRETE   (Greece)

Author keywords

Biologic agents; Greece; Patient access; Pharmaceutical policy; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; AGED; ARTICLE; DRUG COST; FEMALE; GREECE; HEALTH CARE ACCESS; HEALTH INSURANCE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH SERVICE; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; URBAN AREA;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COMMUNITY PHARMACY SERVICES; DRUG COSTS; ECONOMIC RECESSION; FEMALE; GREECE; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; OFFICE VISITS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; RHEUMATOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892601415     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2866-1     Document Type: Article

References (25)

1. Donabedian A (1992) Defining and measuring the quality in health care, in Assessing Quality Health Care. In: Wenzel RP (ed) Perspectives for Clinicians. Williams and Wilkins, Baltimore
2. Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Bijlsma JWJ, Leufkens HGM (2012) Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy 104(1):76-83
3. Miltenburger C, Günther OH, Justo N, Karampampa K, Texier-Richard B, Schweikert B. (2009) A survey of barriers to treatment access in rheumatoid arthritis in France, Germany, Italy, Spain and the UK. Available from: http://www.comparatorreports.se/RA%20Barrier%20Report-FINAL-050110.pdf
4. Garneau KL, Iversen MD, Tsao H, Solomon DH (2011) Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement. Arthr Res Ther 13:R189
5. Hagglund KJ, Clark MJ, Hilton SA, Hewett JE (2005) Access to healthcare services among persons with osteoarthritis and rheumatoid arthritis. Am J Phys Med Rehabil 84(9):702-711
6. Bernatsky S, Feldman D, De Civita M, Haggerty J, Tousignant P, Legaré J, Zummer M, Meagher T, Mill C, Roper M, Lee J (2010) Optimal care for rheumatoid arthritis: a focus group study. Clin Rheumatol 29(6):645-657
7. Westhoff G, Schneider M, Raspe H, Zeidler H, Runge C, Volmer T, Zink A (2009) Advance and unmet need of health care for patients with rheumatoid arthritis in the German population - results from the German rheumatoid arthritis population survey (GRAPS). Rheumatology 48:650-657
8. Põlluste K, Kallikorm R, Meiesaar K, Lember M (2012) Satisfaction with access to health services: the perspective of Estonian patients with rheumatoid arthritis. Sci W J 2012:257569
9. de Boer D, Delnoij D, Rademakers J (2010) Do patient experiences on priority aspects of health care predict their global rating of quality of care? A study in five patient groups. Health Expect 13(3):285-297
10. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis comparison of two cohorts who received different treatment strategies. Am J Med 111(6):446-451
11. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43(7):906-914
12. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975
13. Pugner KM, Scott DI, Holmes JW, Hieke K (2000) The costs of rheumatoid arthritis: an international long-term view. Sem Arthr Rheum 29:305-320
14. Callahan LF (1998) The burden of rheumatoid arthritis: facts and figures. J Rheumatol Suppl 53:8-12
15. Irvine S, Munro R, Porter D (1999) Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Ann Rheum Dis 58(8):510-513
16. Boonen A, Severens JL (2011) The burden of illness of rheumatoid arthritis. Clin Rheumatol 1:S3-S8
17. Doan QV, Chiou CF, Dubois RW (2006) Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 12(7):555-569
18. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE, American College of Rheumatology (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762-784
19. Athanasakis K, Detsis M, Souliotis K, Golna C, Kyriopoulos J (2012) Greek NHS capacity constraints regarding intravenous treatment for rheumatoid arthritis patients. Rheumatol Int 32(4):921-926
20. National Organization for Medicine, available from: http://www.eof.gr/ web/guest/protocols?p-p-id=20&p-p-lifecycle=0&p-p-state= maximized&p-p-mode=view&p-p-col-id=column-1&p-p-col-count=1&-20
21. Hernandez AC, Boumpas D, Drosos D, Galanopoulos N, Sakas L, Setas L, Sidiropoulos P, Christaki S, Tzioufas A, Athanasakis K, Vitsou E, Petrakis I (2012) Rheumatoid arthritis in Greece: the economic burden and impact on quality of life; interim analysis of the HORA study. Hell Rheumatol 23(4):28
22. Tountas Y, Oikonomou N, Pallikarona G, Dimitrakaki C, Tzavara C, Souliotis K, Mariolis A, Pappa E, Kontodimopoulos N, Niakas D (2011) Sociodemographic and socioeconomic determinants of health services utilization in Greece: the Hellas Health I study. Health Serv Manag Res 24(1):8-18
23. Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, Swinkels HL, van der Heijde DM (2004) The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arth Rheum 50(7):2082-2093
24. Laires PA, Exposto F, Mesquita R, Martins AP, Cunha-Miranda L, Fonseca JE (2012) Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. Eur J Health Econ 1-11
25. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A (2013) Working Group 'Equity in access to treatment of rheumatoid arthritis in Europe'. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis